A combination of standard therapy and canakinumab, a monoclonal antibody that targets IL-1β and the inflammasome, was shown to reduce the risk of heart attack, stroke, or related mortality rates in patients with a history of a heart attack (and have elevated CRP levels) (49) compared to the placebo group. This evidence concerns the gene IL1B and myocardial infarction.